Other potential biomarkers, such as gene expression signatures, DNA mutations, and the tumour immune microenvironment, could predict the responsiveness of patients with ER+/HER2+ disease to endocrine therapies (Dieci et al. 2020). Here, ESR1 is linked to neoplasm.